BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 28456021)

  • 21. B cells infected with Type 2 Epstein-Barr virus (EBV) have increased NFATc1/NFATc2 activity and enhanced lytic gene expression in comparison to Type 1 EBV infection.
    Romero-Masters JC; Huebner SM; Ohashi M; Bristol JA; Benner BE; Barlow EA; Turk GL; Nelson SE; Baiu DC; Van Sciver N; Ranheim EA; Gumperz J; Sherer NM; Farrell PJ; Johannsen EC; Kenney SC
    PLoS Pathog; 2020 Feb; 16(2):e1008365. PubMed ID: 32059024
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mechanism of activation of the BNLF2a immune evasion gene of Epstein-Barr virus by Zta.
    Almohammed R; Osborn K; Ramasubramanyan S; Perez-Fernandez IBN; Godfrey A; Mancini EJ; Sinclair AJ
    J Gen Virol; 2018 Jun; 99(6):805-817. PubMed ID: 29580369
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interplay between PKCδ and Sp1 on histone deacetylase inhibitor-mediated Epstein-Barr virus reactivation.
    Tsai PF; Lin SJ; Weng PL; Tsai SC; Lin JH; Chou YC; Tsai CH
    J Virol; 2011 Mar; 85(5):2373-85. PubMed ID: 21159880
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epstein-Barr Virus miR-BHRF1-3 Targets the BZLF1 3'UTR and Regulates the Lytic Cycle.
    Fachko DN; Chen Y; Skalsky RL
    J Virol; 2022 Feb; 96(4):e0149521. PubMed ID: 34878852
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular Basis of Epstein-Barr Virus Latency Establishment and Lytic Reactivation.
    Murata T; Sugimoto A; Inagaki T; Yanagi Y; Watanabe T; Sato Y; Kimura H
    Viruses; 2021 Nov; 13(12):. PubMed ID: 34960613
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Luteolin inhibits Epstein-Barr virus lytic reactivation by repressing the promoter activities of immediate-early genes.
    Wu CC; Fang CY; Hsu HY; Chen YJ; Chou SP; Huang SY; Cheng YJ; Lin SF; Chang Y; Tsai CH; Chen JY
    Antiviral Res; 2016 Aug; 132():99-110. PubMed ID: 27185626
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MYC Controls the Epstein-Barr Virus Lytic Switch.
    Guo R; Jiang C; Zhang Y; Govande A; Trudeau SJ; Chen F; Fry CJ; Puri R; Wolinsky E; Schineller M; Frost TC; Gebre M; Zhao B; Giulino-Roth L; Doench JG; Teng M; Gewurz BE
    Mol Cell; 2020 May; 78(4):653-669.e8. PubMed ID: 32315601
    [TBL] [Abstract][Full Text] [Related]  

  • 28. IRF4 promotes Epstein-Barr virus activation in Burkitt's lymphoma cells.
    Gao Y; Wang L; Lei Z; Li J; Forrest JC; Liang X
    J Gen Virol; 2019 May; 100(5):851-862. PubMed ID: 30907723
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A role for the nucleosome assembly proteins TAF-Iβ and NAP1 in the activation of BZLF1 expression and Epstein-Barr virus reactivation.
    Mansouri S; Wang S; Frappier L
    PLoS One; 2013; 8(5):e63802. PubMed ID: 23691099
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cellular transcription factor Oct-1 interacts with the Epstein-Barr virus BRLF1 protein to promote disruption of viral latency.
    Robinson AR; Kwek SS; Hagemeier SR; Wille CK; Kenney SC
    J Virol; 2011 Sep; 85(17):8940-53. PubMed ID: 21697476
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epstein-Barr virus (EBV) EB1/Zta protein provided in trans and competent for the activation of productive cycle genes does not activate the BZLF1 gene in the EBV genome.
    Le Roux F; Sergeant A; Corbo L
    J Gen Virol; 1996 Mar; 77 ( Pt 3)():501-9. PubMed ID: 8601788
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Topoisomerase I and RecQL1 function in Epstein-Barr virus lytic reactivation.
    Wang P; Rennekamp AJ; Yuan Y; Lieberman PM
    J Virol; 2009 Aug; 83(16):8090-8. PubMed ID: 19494003
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Protein inhibitor of activated STAT1 (PIAS1) inhibits IRF8 activation of Epstein-Barr virus lytic gene expression.
    Zhang K; Lv DW; Li R
    Virology; 2020 Jan; 540():75-87. PubMed ID: 31743858
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Contributions of CTCF and DNA methyltransferases DNMT1 and DNMT3B to Epstein-Barr virus restricted latency.
    Hughes DJ; Marendy EM; Dickerson CA; Yetming KD; Sample CE; Sample JT
    J Virol; 2012 Jan; 86(2):1034-45. PubMed ID: 22072770
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression of Rta in B Lymphocytes during Epstein-Barr Virus Latency.
    Hwang SP; Huang LC; Wang WH; Lin MH; Kuo CW; Huang HH; Chang LK
    J Mol Biol; 2020 Sep; 432(19):5227-5243. PubMed ID: 32710985
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epstein-Barr Virus BZLF1-Mediated Downregulation of Proinflammatory Factors Is Essential for Optimal Lytic Viral Replication.
    Li Y; Long X; Huang L; Yang M; Yuan Y; Wang Y; Delecluse HJ; Kuang E
    J Virol; 2016 Jan; 90(2):887-903. PubMed ID: 26537683
    [TBL] [Abstract][Full Text] [Related]  

  • 37. LMP1-Induced Sumoylation Influences the Maintenance of Epstein-Barr Virus Latency through KAP1.
    Bentz GL; Moss CR; Whitehurst CB; Moody CA; Pagano JS
    J Virol; 2015 Aug; 89(15):7465-77. PubMed ID: 25948750
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Histone acetylation and reactivation of Epstein-Barr virus from latency.
    Jenkins PJ; Binné UK; Farrell PJ
    J Virol; 2000 Jan; 74(2):710-20. PubMed ID: 10623733
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Switching of EBV cycles between latent and lytic states.
    Murata T; Tsurumi T
    Rev Med Virol; 2014 May; 24(3):142-53. PubMed ID: 24339346
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identifying the Cellular Interactome of Epstein-Barr Virus Lytic Regulator Zta Reveals Cellular Targets Contributing to Viral Replication.
    Zhou Y; Heesom K; Osborn K; AlMohammed R; Sweet SM; Sinclair AJ
    J Virol; 2020 Jan; 94(3):. PubMed ID: 31694936
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.